Skip to content

Study · Animal study (in vivo) · mouse · 1993

7 results

Antitumor effect of thymosin alpha 1/interleukin-2 or thymosin alpha 1/interferon alpha,beta following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells.

Garaci E, Pica F, Mastino A, Palamara AT, Belardelli F, Favalli C

Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy1 Jan 1993Cited by 30 (Europe PMC)

PMID8435433 (opens in a new tab)DOI10.1097/00002371-199301000-00002 (opens in a new tab)PepBankPUB-08435433
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with Friend erythroleukemia, cyclophosphamide with a single cytokine but without thymosin alpha‑1 did not produce the tumor regression and cures seen with the thymosin alpha‑1 combinations.

    In plain wordsIn mice with leukemia, cyclophosphamide plus one immune drug, without thymosin alpha‑1, did not give the tumor regression seen with it.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTumor regression and cure with versus without thymosin alpha 1
    Study

    mousen: not reported in source

    DBA/2 mice challenged with Friend erythroleukemia cells
    Comparator
    Cyclophosphamide with a single cytokine, without thymosin alpha 1
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    Neither immunotherapy alone nor CY, alone or in combination with single cytokines, produced similar effects.
    1 context sentence
    Summary · context
    Both treatments resulted in the complete regression of subcutaneous tumor and cured a significative percentage of mice.

Studies that did not test the peptide alone6

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 02AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In mice with Friend erythroleukemia, thymosin alpha‑1 plus interleukin-2 or interferon alpha,beta after cyclophosphamide caused complete regression of subcutaneous tumor.

    In plain wordsIn mice with leukemia, thymosin alpha‑1 combined with another immune drug after chemotherapy made the skin tumors disappear.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseRegression of subcutaneous tumor
    Study

    mousen: not reported in source

    DBA/2 mice challenged with Friend erythroleukemia cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Both treatments resulted in the complete regression of subcutaneous tumor and cured a significative percentage of mice.
    1 context sentence
    Summary · context
    We investigated the effects of the systemic administration of thymosin alpha 1 plus relatively low doses of human recombinant interleukin-2 or very low doses of interferon alpha,beta in untreated and cyclophosphamide (CY)-treated DBA/2 mice challenged either subcutaneously or intravenously (i.v.) wi…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 03AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In mice with Friend erythroleukemia, thymosin alpha‑1 plus interleukin-2 or interferon alpha,beta after cyclophosphamide cured a significant percentage of mice.

    In plain wordsIn mice with leukemia, thymosin alpha‑1 combined with another immune drug after chemotherapy cured a share of the mice.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCure rate
    Study

    mousen: not reported in source

    DBA/2 mice challenged with Friend erythroleukemia cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Both treatments resulted in the complete regression of subcutaneous tumor and cured a significative percentage of mice.
    1 context sentence
    Summary · context
    We investigated the effects of the systemic administration of thymosin alpha 1 plus relatively low doses of human recombinant interleukin-2 or very low doses of interferon alpha,beta in untreated and cyclophosphamide (CY)-treated DBA/2 mice challenged either subcutaneously or intravenously (i.v.) wi…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 04AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In mice injected intravenously with large numbers of Friend erythroleukemia cells, thymosin alpha‑1 plus interleukin-2 or interferon alpha,beta after cyclophosphamide increased survival time.

    In plain wordsIn mice with leukemia, thymosin alpha‑1 combined with another immune drug after chemotherapy lengthened survival.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSurvival of mice injected intravenously
    Study

    mousen: not reported in source

    DBA/2 mice challenged with Friend erythroleukemia cells
    Outcome group
    Mortality · Cancer

    Source sentences

    Summary
    They also increased the survival time of mice i.v. injected with large numbers of FLC.
    1 context sentence
    Summary · context
    We investigated the effects of the systemic administration of thymosin alpha 1 plus relatively low doses of human recombinant interleukin-2 or very low doses of interferon alpha,beta in untreated and cyclophosphamide (CY)-treated DBA/2 mice challenged either subcutaneously or intravenously (i.v.) wi…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 05AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism

    In treated mice, the thymosin alpha‑1 combination protocols produced a synergistic increase in the cytotoxicity of spleen cells.

    In plain wordsIn mice, thymosin alpha‑1 combined with another immune drug after chemotherapy raised the tumor-killing power of spleen cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCytotoxicity of spleen cells
    Study

    mousen: not reported in source

    DBA/2 mice challenged with Friend erythroleukemia cells
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    a synergistic increase of the cytotoxicity of spleen cells was demonstrated in treated mice
    1 context sentence
    Summary · context
    We investigated the effects of the systemic administration of thymosin alpha 1 plus relatively low doses of human recombinant interleukin-2 or very low doses of interferon alpha,beta in untreated and cyclophosphamide (CY)-treated DBA/2 mice challenged either subcutaneously or intravenously (i.v.) wi…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 06AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism

    In mice, selective in vivo depletion of asialo-GM1, CD4 or CD8 positive cells abrogated the antitumor activity of the thymosin alpha‑1 combination protocols.

    In plain wordsIn mice, removing certain immune cells cancelled the anti-tumor effect of thymosin alpha‑1 combined with another immune drug.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableDepletion of asialo-GM1, CD4 or CD8 cells
    Study

    mousen: not reported in source

    DBA/2 mice challenged with Friend erythroleukemia cells
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    selective in vivo depletion of asialo-GM1, CD4, or CD8-positive cells abrogated this antitumor activity
    1 context sentence
    Summary · context
    We investigated the effects of the systemic administration of thymosin alpha 1 plus relatively low doses of human recombinant interleukin-2 or very low doses of interferon alpha,beta in untreated and cyclophosphamide (CY)-treated DBA/2 mice challenged either subcutaneously or intravenously (i.v.) wi…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 07AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism

    In treated mice, a high lymphoid cell infiltration was found at the tumor site and in the livers.

    In plain wordsIn mice given thymosin alpha‑1 combined with another immune drug after chemotherapy, many immune cells gathered at the tumor and in the liver.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseLymphoid cell infiltration
    Study

    mousen: not reported in source

    DBA/2 mice challenged with Friend erythroleukemia cells
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    a high lymphoid cell infiltration was found at the tumor site and in the livers of treated mice.
    1 context sentence
    Summary · context
    We investigated the effects of the systemic administration of thymosin alpha 1 plus relatively low doses of human recombinant interleukin-2 or very low doses of interferon alpha,beta in untreated and cyclophosphamide (CY)-treated DBA/2 mice challenged either subcutaneously or intravenously (i.v.) wi…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.